SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $1,587,937,058 |
| Positions | 26 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| Trevi Therapeutics, Inc. | TRVI | COM | $246,594,552 | 13,222,228 |
| MBX Biosciences, Inc. | MBX | COM | $199,519,627 | 3,614,486 |
| Monte Rosa Therapeutics, Inc. | GLUE | COM | $186,153,612 | 7,692,298 |
| Celcuity Inc. | CELC | COM | $178,958,892 | 1,710,561 |
| Spyglass Pharma, Inc. | SGP | COM SHS | $164,552,620 | 7,392,301 |
| Savara, Inc. | SVRA | COM | $150,742,986 | 24,471,264 |
| Zenas BioPharma, Inc. | ZBIO | COM | $102,109,298 | 4,023,219 |
| Coursera, Inc. | COUR | COM | $72,574,217 | 12,867,769 |
| Aurinia Pharmaceuticals, Inc. | AUPH | COM | $67,368,083 | 3,969,834 |
| CRISPR Therapeutics AG | CRSP | NAMEN AKT | $57,734,408 | 1,058,570 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.